European Stroke Organization Guidelines for the Management of Intracranial Aneurysms and Subarachnoid Haemorrhage by Steiner, Thorsten et al.




 Cerebrovasc Dis 2013;35:93–112
 DOI: 10.1159/000346087 
 European Stroke Organization Guidelines for 
the Management of Intracranial Aneurysms 
and Subarachnoid Haemorrhage 
 Thorsten Steiner   a     Seppo Juvela   d     Andreas Unterberg   b     Carla Jung   b     
Michael Forsting   c     Gabriel Rinkel   e  
 Departments of  a   Neurology and  b   Neurosurgery, Heidelberg University,  Heidelberg , and  c   Department of 
Radiology, University of Essen,  Essen , Germany;  d   Department of Clinical Neurosciences, University of Helsinki, 
 Helsinki , Finland;  e   Department Neurology, Utrecht University,  Utrecht , The Netherlands
 
European Federation of Neurological Societies. Members of 
the Guidelines Committee of the European Stroke Organiza-
tion reviewed the guidelines.  Results: These guidelines pro-
vide evidence-based information on epidemiology, risk fac-
tors and prognosis of SAH and recommendations on diag-
nostic and therapeutic methods of both ruptured and 
unruptured intracranial aneurysms. Several risk factors of an-
eurysm growth and rupture have been identified. We provide 
recommendations on diagnostic work up, monitoring and 
general management (blood pressure, blood glucose, tem-
perature, thromboprophylaxis, antiepileptic treatment, use 
of steroids). Specific therapeutic interventions consider tim-
ing of procedures, clipping and coiling. Complications such 
as hydrocephalus, vasospasm and delayed ischaemic deficit 
were covered. We also thought to add recommendations on 
SAH without aneurysm and on unruptured aneurysms.  Con-
clusion: Ruptured intracranial aneurysm with a high rate of 
subsequent complications is a serious disease needing 
prompt treatment in centres having high quality of experi-
ence of treatment for these patients. These guidelines pro-
vide practical, evidence-based advice for the management of 
patients with intracranial aneurysm with or without rupture. 
Applying these measures can improve the prognosis of SAH. 
 Copyright © 2013 S. Karger AG, Basel 
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 Abstract 
 Background: Intracranial aneurysm with and without sub-
arachnoid haemorrhage (SAH) is a relevant health problem: 
The overall incidence is about 9 per 100,000 with a wide 
range, in some countries up to 20 per 100,000. Mortality rate 
with conservative treatment within the first months is 50–
60%. About one third of patients left with an untreated aneu-
rysm will die from recurrent bleeding within 6 months after 
recovering from the first bleeding. The prognosis is further 
influenced by vasospasm, hydrocephalus, delayed ischaemic 
deficit and other complications. The aim of these guidelines 
is to provide comprehensive recommendations on the man-
agement of SAH with and without aneurysm as well as on 
unruptured intracranial aneurysm.  Methods: We performed 
an extensive literature search from 1960 to 2011 using Med-
line and Embase. Members of the writing group met in per-
son and by teleconferences to discuss recommendations. 
Search results were graded according to the criteria of the 
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 General Considerations 
 Introduction 
 Subarachnoid haemorrhage (SAH) is a relevant 
health problem with an approximate incidence of 9 per 
100,000 and a mortality rate of about 60% within 6 
months. The prognosis is influenced by multiple non-
modifiable factors and by factors that can be influenced 
by therapeutic interventions and management proce-
dures. International guidelines are only available in the 
United States  [1] . However, those guidelines mainly deal 
with SAH from ruptured aneurysm and there might be 
some differences in the conception of technical and 
management aspects and in terms of epidemiology. 
Therefore, it is necessary to publish guidelines on the 
management of SAH and unruptured aneurysms from 
a European standpoint.
 The writing group consists of experts in neurology, 
neurosurgery, neuroradiology and neurointensive care 
medicine. We performed a literature search including all 
available literature using Medline and Embase. Literature 
was evaluated and assessed using the predefined criteria 
of the European Federation of Neurological Societies  [2] . 
Level of evidence is reported in classes from I to IV. Rec-
ommendations are rated by levels A–C and GCP (good 
clinical practice).
 Definitions – Terminology 
 Statement on Definition 
 • We differentiate ‘ruptured intracranial aneurysm’ (RIA) from 
‘unruptured intracranial aneurysm’ (UIA); the latter can ei-
ther be ‘asymptomatic’ or ‘symptomatic’  
 • A symptomatic UIA usually causes brain nerve palsy or rarely 
can cause arterial embolism  
 • Asymptomatic UIAs are usually found incidentally (‘inci-
dental aneurysm’) because of symptoms unrelated to aneu-
rysm (long-term headache, dizziness, etc.) or can be discov-
ered after SAH as an ‘additional aneurysm’, which is not the 
bleeding source 
 Clinical Appearance and Grading 
 In aneurysmal SAH three variables are most closely 
related to outcome: the neurological condition of the 
patient on admission, age, and the amount of extrava-
sated blood seen on CT scans. The neurological condi-
tion, particularly the level of consciousness, is the most 
important determinant for outcome after SAH. There-
fore, since the neurological condition can change dur-
ing the clinical course after SAH, it is important to have 
a reliable (i.e. high inter- and intra-observer agreement) 
and valid (i.e. good relation with outcome) grading sys-
tem for unequivocal and understandable documenta-
tion. Several grading systems, in most cases consisting 
of approximately 5 categories of severity, have been de-
veloped for the initial assessment of SAH patients. A 
still widely used scale is that of Hunt and Hess  [3] : be-
sides the level of consciousness (graded into drowsiness, 
stupor and deep coma), headache (minimal, moderate 
and severe), neck stiffness (slight nuchal rigidity vs. nu-
chal rigidity) and focal neurological deficits (mild, 
moderate and severe hemiparesis) constitute this scale. 
Due to the unclear definition of the neurological status 
described above, this scale is neither reliable nor valid 
 [4] . As grading scales based on the Glasgow Coma Scale 
(GCS) have the advantage of a reasonable inter-observ-
er agreement, a committee of the World Federation of 
Neurological Surgeons (WFNS) proposed a grading 
scale of again five levels, essentially based on the GCS, 
with focal deficits making up one extra level for patients 
with a GCS of 14 or 13  [5] . The cut-off points in the 
WFNS scale are based on consensus, not on formal 
analysis. Another scale based on the GCS, and assessed 
only retrospectively, performed better than the Hunt 
and Hess scale and the WFNS scale  [6] . For one grading 
scale based solely on the GCS, the Prognosis on Admis-
sion of Aneurysmal Subarachnoid Haemorrhage 
(PAASH) grading scale, the cut-off points between the 
categories were selected by calculating at which point 2 
consecutive categories corresponded to a statistically 
significant different outcome at 6 months  [7] . This 
PAASH scale has a good internal and external validity 
in regard to clinical outcome  [8] . In a study comparing 
prognostic accuracy, both scales, WFNS and PAASH, 
had a good prognostic value for patient outcome. How-
ever, the PAASH scale showed a more gradual increase 
in the proportionate distribution of patients with poor 
outcome per each increasing PAASH grade than the 
WFNS scale and seems, therefore, slightly preferable to 
the WFNS scale ( table 1 )  [8] .
 Recommendation 
 • It is recommended that the initial assessment of SAH pa-
tients, and therefore the grading of the clinical condition, is 
done by means of a scale based on the GCS 
 • The PAASH scale performs slightly better than the WFNS 
scale, which has been used more often  
 (class III, level C)
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 Aneurysmal SAH – Ruptured Aneurysm (RIA) 
 Epidemiology  
 Incidence 
 The incidence of SAH varies widely throughout the 
world. An estimate of 9.1 (95% confidence interval, CI, 
8.8–9.5) per 100,000 per year is generally accepted as the 
overall incidence of SAH worldwide, with the exclusion 
of the regionally high incidences in Finland and Japan  [9] . 
In Finland and Japan incidences of SAH of 15–17 per 
100,000 per year during the CT era and of 22.7 per 100,000 
per year (95% CI, 21.9–23.5) were reported, respectively 
 [9–12] . SAH incidence increases linearly with patient age. 
The median age of onset at the first SAH is 50–60 years. 
Furthermore, the incidence of SAH is approximately 1.6 
times higher in women than in men, but the predomi-
nance of women is not apparent until the fifth decade 
 [9–11] . In general, there is a tendency of reduction in in-
cidence during later decades  [9, 10, 12] .
 Intracranial aneurysms in the general population as 
well as in selected populations have been studied in vari-
ous retrospective and prospective autopsy and angiogra-
phy studies  [11] . Among adults, the prevalence appears to 
be 2–5%. Reported frequencies of unruptured aneurysms 
in angiographic and prospective autopsy series is approx-
imately 3–4%  [11] . Those with a family history of aneu-
rysms have a higher prevalence of 9.5%. More than 90% 
of aneurysms are less than 10 mm in diameter and 90% 
exist in anterior cerebral circulation.
 Statement on Incidence 
 • The overall incidence of SAH is 9.1 per 100,000 person-years 
in most regions, and is higher in Finland and Japan; in the 
European community that means around 36,000 SAH cases 
per year 
 Outcome/Prognosis 
 Data on the natural history of aneurysmal SAH is very 
poor. The most reliable knowledge of the natural history 
of ruptured saccular intracranial aneurysms has been ob-
tained from a study reported by Pakarinen  [13] with an 
unselected population and few surgical withdrawals  [13, 
14] . Cumulative case fatality rates over time after SAH are 
as follows: day 1: 25–30%; week 1: 40–45%; first month: 
50–60%; sixth month: 55–60%; year 1: 65% and year 5 
after SAH: 65–70%. Approximately 12% of patients die 
before reaching medical attention  [15] .
 If those patients who die before medical attention are 
included, 43% of all SAH patients die without recovering 
from the initial bleeding  [13] . Of those, 74% die within 
the first 24 h, 7% within 2–3 days, 12% within 4–7 days, 
5% within week 2, 1% within week 3, and 1% later than 3 
weeks after the initial SAH  [13] .
 If a ruptured aneurysm is left untreated, about one third 
of the patients who recover from the initial haemorrhage 
die because of recurrent bleeding within 6 months after 
SAH  [13, 16] . The cumulative risk of rebleeding by 6 months 
after SAH is 50%. Thereafter, the annual risk of rebleeding 
decreases to 3% during the next 10 years. Two thirds of 
these late, recurrent bleedings cause death  [17–19] .
 Despite improvements in surgical and medical treat-
ment, rupture of an aneurysm is still associated with high 
rates of case fatality (roughly one third) and of severe dis-
ability (one sixth)  [14, 20] . Between 1973 and 2002 case 
fatality rate decreased by approximately 17%  [21] , and the 
possibility to recover an independent state has increased 
by 1.5% per year  [14] . However, data on recovery are based 
only on a few studies with a small number of patients.
 Case fatality and functional outcome after SAH are 
determined by the severity of the initial bleeding  [14, 22, 
23] . Another very important parameter is age, with a tri-
pled case fatality in octogenarians compared with young 
adults  [22–26] . Other determinants are aneurysm site 
 [24] and size  [23, 24] , history of hypertension  [22–24] , 
high systolic blood pressure  [23] and heavy alcohol con-
Table 1.  Two SAH grading scales with criteria per grade and 
relation with outcome






WFNS I GCS 15 14.8% reference
II GCS 13–14





IV GCS 7–12 58.3% 7.7
V GCS 3–6 92.7% 69
PAASH I GCS 15 14.8% reference
II GCS 11–14 41.3% 3.9
III GCS 8–10 74.4% 16
IV GCS 4–7 84.7% 30
V GCS 3 93.9% 84
 Poor outcome defined as Glasgow outcome scale 1–3 or mod-
ified Rankin score 4–6. WFNS = World Federation of Neurologi-
cal Surgeons Grading Scale for Subarachnoid Haemorrhage [5]. 
PAASH = Prognosis on Admission of Aneurysmal Subarachnoid 
Haemorrhage grading scale [7]. GCS = Glasgow Coma Score [157]. 






sumption  [22] . All these factors have been reported inde-
pendently of the severity of SAH to predict outcome. In 
addition, in a large meta-analysis cigarette smoking has 
been reported to increase the risk for delayed cerebral 
ischaemia (DCI)  [27] . The role of biomarkers for evalua-
tion has not been studied in large cohorts. Small studies 
suggest that catecholamine levels in cerebrospinal fluid 
(CSF) are elevated in patients who experience early mor-
tality or disability  [28] . Serum S100 has been associated 
with poor outcome after SAH  [29] .
 After aneurysm rupture, the possibility of poor out-
come rises because of different factors: (1) disease-associ-
ated events (e.g. rebleeding, DCI, hydrocephalus), (2) 
treatment-associated factors [surgical (clipping) or endo-
vascular (coiling) complications] and (3) complications 
associated with prolonged bed rest  [14, 22–24, 30] . Aneu-
rysm rupture itself can cause stress hyperglycaemia, car-
diopulmonary complications and increased blood coag-
ulability, which, independent of severity of bleeding or of 
metabolic syndrome, may elevate the risk of poor out-
come  [25, 30–32] . Outcome after SAH is thus probably 
determined by multiple independent factors.
 There are not many data on health-related quality of 
life (HRQoL) after SAH. HRQoL may be remarkably re-
duced in patients with SAH compared to the normal pop-
ulation. Female gender, severe SAH, functional disability, 
depression, lower level of education and the lack of a sta-
ble partnership were found to be independent predictors 
of HRQoL  [33] .
 Risk Factors 
 Risk Factors can be divided into risk factors for SAH, 
aneurysm formation and aneurysm growth.
 Independent modifiable risk factors for SAH seem to 
be only cigarette smoking, excessive alcohol consump-
tion and hypertension (class III evidence)  [34–36] .
 Cigarette Smoking 
 Cigarette smoking is an independent and the most im-
portant risk factor for SAH, which has already been 
proved in several cohort (relative risk, RR of current 
smoking, 2.2) and case-control studies (odds ratio, OR, 
3.1) all over the world  [34–38] . In North America and Eu-
rope, the prevalence of smoking in SAH patients ranges 
from 45 to 75% whereas in the general adult population 
it is 20–35%. Of SAH cases, 40% can be attributed to cig-
arette smoking  [35–39] .
 After diagnosis of an unruptured aneurysm, the size 
of aneurysm  [40–42] , and possibly location  [41] , age in-
versely  [42] and cigarette smoking  [42] are independent 
predictors for subsequent aneurysm rupture. The ad-
justed RR of cigarette smoking for aneurysm rupture, 
tested as a time-dependent covariate, was 3.0 (95% CI, 
1.2–7.7) if the patient continued smoking during follow-
up  [42] .
 In a prospective follow-up study, cigarette smoking 
and female gender were only significant independent 
factors affecting both aneurysm formation and growth 
 [43] . Women in particular were at higher risk for aneu-
rysm formation than men, and cigarette smoking has-
tened aneurysm growth rate. These findings are impor-
tant since aneurysms grow before the rupture. The fast-
er the growth, the more likelihood there is of rupture 
 [43] .
 Alcohol Use 
 The role of alcohol as a risk factor for SAH has not 
been as well established as smoking. Several cohort (RR 
>150 g/week, 2.1) and case-control (OR >150 g/week, 
1.5) studies have shown that excessive alcohol consump-
tion increases the risk for SAH in both men and women, 
independently of cigarette smoking, age, and history of 
hypertension  [34–38] . In the study from Ruigrok et al. 
 [39] , drinking more than 300 g/week of alcohol attrib-
uted to 20% of instances of SAH in the population, and 
drinking 100–299 g/week accounted for 11% of cases of 
SAH  [36, 39] .
 Hypertension 
 History of hypertension as a risk factor for SAH (RR, 
2.5; OR, 2.6) seems to be less crucial than for other 
stroke subtypes  [34–38] . The prevalence of hyperten-
sion among SAH patients (20–45%) is somewhat higher 
than in the general population; after adjustment for age, 
gender, cigarette smoking and alcohol consumption, 
history of hypertension has not been shown to signifi-
cantly increase the risk for SAH, as demonstrated in 2 
case-control studies  [36, 38] . However, combining all 
cohort and case-control studies, hypertension still was 
an important risk factor  [34] .
 In a long-term cohort study, patients with hyperten-
sion did not have de novo aneurysms or aneurysm growth 
more often than non-hypertensive patients, nor did blood 
pressure values during follow-up correlate with aneu-
rysm formation or growth  [43] . However, patients who 
had used antihypertensive medication may have de-
creased risk for aneurysm formation  [43] . On the other 
hand, in another long-term follow-up study hypertension 
at the time of the initial SAH was a risk factor for de novo 
aneurysm formation  [44] .
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 • Hypertension can be considered to be an important risk factor 
for SAH and possibly for aneurysm formation and fatal aneu-
rysm rupture 
 • Cigarette smoking is the most important modifiable risk fac-
tor for aneurysm formation, growth and rupture, and should 
be discouraged 
 • Alcohol abuse and particularly sudden intake of high quanti-
ties is a risk factor for aneurysm rupture and should be de-
sisted 
 (class III, level C)
 Family History 
 Recently, family history of intracranial aneurysms has 
been suggested to be evidence for genetic causality of ce-
rebral aneurysms  [35, 45–47] . However, cigarette smok-
ing and other health-related habits should be analysed as 
a confounding factor for this association since correlation 
of these habits between family members is higher than in 
the general population  [45, 48] . Smoking and alcohol in-
take habits may even to some degree be influenced by 
genetic factors  [48] . Part of the familial preponderance 
may also be attributed to familial occurrence of hyper-
tension  [49, 50] .
 Less than 10% of SAH can be attributed to first-degree 
relatives only  [35, 39, 45] , and 5–8% to first or second-
degree relatives  [35, 45] . Also, many studies show that 
around 10% of patients with SAH have a family history. 
The chance of finding an aneurysm at screening is around 
10% if 2 or more first-degree relatives are affected  [51–57] . 
A family history of polycystic kidney disease seems to 
increase the risk of SAH  [11] .
 Recommendation 
 • Screening should in general not be advised in the case of only 
1 affected first-degree relative  
 • If 2 or more first-degree relatives are affected, the lifetime risk 
of SAH in the other relatives is considerable, and screening 
should be considered 
 (class III, level C)
 Other Risk Factors 
 Besides the above-mentioned risk factors many other 
factors have been implicated in the pathogenesis of sac-
cular aneurysms and SAH. Of these, non-white ethnic-
ity has been associated with increased risk for SAH, 
while hormone replacement therapy among women, hy-
percholesterolemia, and diabetes mellitus may reduce 
this risk  [34] . According to a recent systematic review, 
the use of oral contraceptives does not seem to affect 
SAH risk, and the significance of low body mass index 
or rigorous exercise seems inconsistent  [34] . Of these, 
low serum total cholesterol and triglyceride levels may be 
independent of cigarette smoking and hypertension risk 
factors for SAH  [58] .
 The annual rate of new (de novo) aneurysm formation 
was 0.6–0.9% in patients with a treated ruptured aneu-
rysm  [43, 59, 60] . These angiographic follow-up studies 
were done for all survivors and not only for those with a 
later new SAH, as this kind of patient selection errone-
ously would have increased this formation rate. Women 
and cigarette smokers had independently increased risk 
(OR, 4–5) for de novo aneurysm formation  [43] . De novo 
aneurysms developed during a mean follow-up time of 
19 years, a follow-up period not differing significantly 
from that of those without de novo aneurysms. In cases 
where a de novo aneurysm caused SAH, the follow-up 
time was somewhat shorter (14.7 ± 8.1 years; range, 3.4–
28.4 years)  [43] .
 MR angiography (MRA) follow-up of 610 patients 
with a mean follow-up of 9 years after SAH revealed a 
cumulative 16% chance of finding a new aneurysm  [44] . 
In this study, risk factors for aneurysm formation and 
growth were the presence of multiple aneurysms at time 
of SAH (hazard ratio, HR, 3.2; 95% CI, 1.2–8.6), current 
smoking (HR, 3.8; 95% CI, 1.5–9.4) and hypertension 
(HR, 2.3; 95% CI, 1.1–4.9).
 Of 752 SAH patients with 6,016 follow-up years (mean 
follow-up 8.0 years), 18 had a recurrence of SAH. In the 
first 10 years after the initial SAH, the cumulative inci-
dence of recurrent SAH was 3.2% (95% CI, 1.5–4.9%) and 
the incidence rate was 286 of 100,000 patient-years (95% 
CI, 160–472 per 100,000). Risk factors were smoking 
(HR, 6.5; 95% CI, 1.7–24.0), age (HR, 0.5 per 10 years; 95% 
CI, 0.3–0.8) and multiple aneurysms at the time of the 
initial SAH (HR, 5.5; 95% CI, 2.2–14.1). Thus, after SAH, 
the incidence of a recurrence within the first 10 years is 
22 (12–38) times higher than expected in populations 
with comparable age and sex. Whether this increased 
risk justifies screening for recurrent aneurysms in pa-
tients with a history of SAH requires further study  [44, 
60] .
 Statement on Risk Factor 
 • Risk factors for SAH can be divided into risk factors for aneu-
rysm formation, aneurysm growth and rupture 
 • The most important modifiable risk factors for SAH: cigarette 
smoking, hypertension and excessive alcohol intake, and non-
modifiable risk factors: sex, age, size of aneurysm and family 
history 
 • Risk factors for de novo formation of aneurysms: female sex, 
current cigarette smoking, hypertension, age (at diagnosis) 
and family history 







 Subarachnoid blood is almost always detectable on CT 
scans on the first day of SAH with its typical distribution 
in the subarachnoid space/basal cisterns. Therefore, if 
SAH is clinically suspected a cranial CT should be per-
formed to confirm the diagnosis. Modern CT technology 
provides a sensitive method to detect subarachnoid blood 
in the early phase after SAH. However, sensitivity of CT 
decreases with resorption and redistribution of sub-
arachnoid blood over the time course after the initial 
SAH: 5 days after the initial bleeding SAH is detectable 
in about 85% of cases and after 2 weeks in under 30% of 
SAH cases. MRI with Flair technology seems comparable 
with CT in the acute phase of SAH  [61] . In the weeks fol-
lowing SAH, MRI is clearly superior to CT  [62] and re-
veals a reliable tool in the follow-up of endovascular-
treated aneurysms. After surgical treatment (clipping) of 
aneurysms MRI is of reduced value due to metal arte-
facts. In the case of anamnestically or clinically suspected 
SAH, despite negative/inconspicuous CT and/or MRI 
scans, a lumbar puncture has to be performed. Water-
clear, normal CSF excludes SAH within the last 2–3 
weeks. In the case of bloody CSF a traumatic tap must be 
kept in mind. More assuring than bloody CSF but not 
specific is the detection of xanthochromia caused by deg-
radation of blood. As blood degradation takes some 
hours, lumbar puncture is recommended 6–12 h after the 
initial SAH.
 Cerebral panangiography continues to be the gold 
standard for detection, demonstration and localization of 
ruptured aneurysms. Complication rate of this invasive 
diagnostic procedure is below 0.5% in experienced cen-
tres  [63] . Further less invasive methods are MRA and CT 
angiography (CTA)  [62, 63] . MRA is a secure procedure, 
which was reported to be less sensitive than digital sub-
traction angiography (DSA, conventional angiography) 
and less feasible in agitated patients or those who require 
monitoring during the acute phase after SAH. CTA is less 
time consuming than MRA. Sensitivity and specificity of 
CTA detecting cerebral aneurysms are described to be 
0.77–0.97 and 0.87–1.00, respectively. However, sensitiv-
ity decreases with aneurysm size: for small aneurysms 
(<3 mm) CTA sensitivity ranges around 0.4–0.9. A simi-
lar loss of sensitivity is reported and observed in MRA 
 [64, 65] . In the context of further prospective improve-
ment of CTA and MRA technology a decrease in DSA is 
anticipated. Recently, Agid et al.  [66] showed that CTA in 
patients with a specific CT pattern of subarachnoid blood 
distribution is as good as DSA.
 Recommendation for Diagnosis 
 • CT/CTA and MRI with multiple sequences are equally suit-
able for the diagnosis of SAH within 24 h (class II, level B) 
 • CT/CTA and multisequential MRI/MRA may confirm the 
underlying cause 
 •  Lumbar puncture must be performed in a case of clinically 
suspected SAH if CT or MRI does not confirm the diagnosis 
(class II, level B); however, within the first 6–12 h the differ-
entiation between genuine subarachnoidal blood and trau-
matic admixture of blood may be difficult 
 • DSA of all cerebral arteries should be performed if a bleeding 
source was not found on CTA and the patient has a typical 
basal SAH pattern on CT (class II, level B) 
 • If no aneurysm was found, CTA or DSA should be repeated 
as described below: SAH without aneurysm (class III, level C) 
 Treatment 
 General Medical Management 
 Monitoring and Physical Management 
 Recommendations for monitoring and general man-
agement are summarized in  table 2 . Patients should be 
under continuous observation in an intensive care unit, 
or in an intermediate care facility of a stroke or neurovas-
cular unit  [67] . Staff in this unit should have ample expe-
rience in assessing swallowing function to prevent pneu-
monia, a frequent complication after SAH and indepen-
dent risk factor for poor outcome  [68] . ECG, level of 
consciousness (GCS), focal deficits, temperature and pu-
pils should be monitored frequently for at least the first 7 
days after SAH, or longer as required depending on the 
patient’s clinical condition. A urinary catheter is advised 
in all patients as well as a calculated fluid balance every 6 
h during the initial week. In the intensive care unit, blood 
pressure is monitored continuously via an arterial line. 
Patients in a good clinical condition in whom the aneu-
rysm has been secured may be transferred to a regular 
care bed in the stroke unit.
 Headache can sometimes be managed with just mild 
analgesics such as paracetamol (acetaminophen); salicy-
lates are best avoided because their antihaemostatic effect 
is unwanted in patients who may have to undergo exter-
nal ventricular drainage and interferes with possibly 
pending neurosurgical interventions. In practice, the 
pain is usually so severe that codeine and even a synthet-
ic opiate might be needed.
 Statement on Physical Management 
 • To avoid situations that increase intracranial pressure, the pa-
tient should be kept in bed and the application of antiemetic 
drugs, laxatives and analgetics should be considered before 
occlusion of the aneurysm (GCP) 
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 Hyperglycaemia develops in one third of SAH pa-
tients. Hyperglycaemia is associated with poor clinical 
condition on admission, and is independently associated 
with poor outcome  [25, 30, 31, 69] . Whether correction of 
hyperglycaemia results in improved outcome remains 
unclear. In a small trial comparing intensive versus con-
ventional insulin therapy, intensive therapy reduced in-
fection rate during the initial 14 days after admission. 
However, the trial was too small to detect differences in 
clinical outcome  [70] (class III, level C).
 Recommendation for Blood Glucose Management 
 • Hyperglycemia over 10 mmol/l should be treated (GCP) 
 Temperature 
 Despite treatment with paracetamol to relieve pain, 
fever develops in more than half of all SAH patients  [71] , 
predominantly in those with poor clinical condition on 
admission and in those with intraventricular extension 
of the haemorrhage  [71] . Furthermore, fever is an inde-
pendent risk factor for poor outcome  [69] . In around 20% 
of patients no infection is found, and fever is attributed 
to inflammatory responses to extravasated blood in the 
subarachnoid space. There are neither controlled studies 
on the effect of cooling in SAH patients nor studies that 
have shown that treatment of fever does improve out-
come. A randomized trial of mild hypothermia (33   °   C) 
during aneurysm surgery after SAH showed no benefit 
 [72] .
 Recommendation for Temperature Management 
 • Increased temperature should be treated medically and phys-
ically (GCP) 
 Arterial Blood Pressure 
 The treatment of high blood pressure after SAH re-
mains controversial because of lack of evidence from 
randomized trials. Data from observational studies sug-
gest that aggressive treatment of blood pressure may de-
crease the risk of rebleeding but at the cost of an in-
creased risk of secondary ischaemia  [73] . It seems rea-
sonable, but without good evidence, to stop any 
antihypertensive medication that the patients were us-
ing and not to treat hypertension unless the blood pres-
sure is extreme. It is not possible to give limits for ‘ex-
treme’ blood pressures, because ‘extreme’ differs in dif-
ferent patients according to their age, previous blood 
pressure, cardiac history and other factors. If the aneu-
rysm is not yet secured it seems prudent to treat blood 
pressure if the systolic pressure exceeds 180 mm Hg, for 
example by means of esmolol or labetolol  [74] ; it seems 
reasonable to aim for a modest (e.g. 25%) decrease in 
mean arterial pressure.
 Recommendation for Blood Pressure Management 
 • Until coiling or clipping, systolic blood pressure should be 
kept below 180 mm Hg; this may be already achieved by 
 applying analgetics and nimodipine (GCP)
 • If systolic pressure remains high despite these treatments fur-
ther lowering of blood pressure should be considered (class 
IV, level C) 
 • If blood pressure is lowered the mean arterial pressure should 
be kept at least above 90 mm Hg (GCP) 
 Thromboprophylaxis 
 In a placebo-controlled trial of enoxaparin (a low-mo-
lecular-weight heparin) administered subcutaneously 40 
Table 2.  Recommendations for monitoring and general manage-
ment of patients with aneurysmal SAH
Monitoring
– Intensive continuous observation at least until occlusion of 
the aneurysm
– Continuous ECG monitoring
– Start with GCS, focal deficits, blood pressure and tempera-
ture at least every hour
Blood pressure
– Stop antihypertensive medication that the patient was using
– Do not treat hypertension unless it is extreme; limits for ex-
treme blood pressures should be set on an individual basis, 
taking into account age of the patient, pre-SAH blood pres-
sures and cardiac history; systolic blood pressure should be 
kept below 180 mm Hg, only until coiling or clipping of rup-
tured aneurysm, to reduce risk for rebleeding
Fluids and electrolytes
– Intravenous line mandatory
– Insert an indwelling urinary catheter
– Start with 3 litre/day (isotonic saline, 0.9%), and adjust infu-
sion for oral intake
– Aim for normovolaemia also in case of hyponatraemia and 
compensate for fever
– Monitor electrolytes, glucose and white blood cell count at 
least every other day
Pain
– Start with paracetamol (acetaminophen) 500 mg every 3–4 h; 
avoid aspirin before aneurysm occlusion
– For severe pain, use codeine, tramadol (suppository or i.v.) or, 
as a last resort, piritramide (i.m. or i.v.)
Prevention of deep venous thrombosis and pulmonary embolism
– Compression stockings and intermittent compression by 






mg once a day after surgical aneurysm occlusion, intra-
cranial bleeding complications occurred somewhat more 
often in the enoxaparin group while there was no overall 
influence on outcome or appearance of post-SAH cere-
bral infarction  [75, 76] . Enoxaparin also increased the in-
cidence of postoperative intracranial haemorrhage when 
initiated pre-operatively for deep venous thrombosis pro-
phylaxis in patients with brain tumours  [77] .
 Because of this increased risk of intracranial bleeding 
from thromboprophylaxis by means of low-molecular-
weight heparins, the use of stockings or pneumatic de-
vices seems more appropriate in SAH patients. A study 
with non-randomized controls suggested that deep vein 
thrombosis can be successfully prevented by the use of 
pneumatic devices  [78] . A Cochrane review on the use of 
graduated compression stockings or intermittent pneu-
matic compression in patients with stroke did not find 
support for the use of either method  [79] . In a randomized 
trial in patients with intracerebral haemorrhage (ICH), 
the combination of stockings and intermittent pneumatic 
compression resulted in a smaller risk of deep venous 
thrombosis than prevention by stockings alone  [80] . This 
combination may be the preferred strategy because there 
is no reason to suppose that this effect would be any dif-
ferent in patients with SAH, but it needs further study.
 Recommendation for Thromboprophylaxis 
 • Patients with SAH may be given thromboprophylaxis with 
pneumatic devices and/or compression stockings before oc-
clusion of the aneurysm (class II, level B) 
 • In case deep vein thrombosis prevention is indicated, low-
molecular-weight heparin should be applied not earlier than 
12 h after surgical occlusion of the aneurysm and immedi-
ately after coiling (class II, level B) 
 Antiepileptic Treatment 
 Seizures at onset occur in around 7% of patients, but 
their impact on prognosis is uncertain  [81] . Another 10% 
develop seizures in the first few weeks  [82] , and convulsive 
status epilepticus occurs in 0.2%  [83] . In patients who are 
comatose, non-convulsive status epilepticus has been de-
tected in 8% of patients  [84] , but the proportion in this 
study might be an overestimation due to selection of EEG 
by indication. Whether continuous EEG monitoring 
should be performed in all SAH patients or in the subset 
that is comatose is an unresolved issue. In 1 retrospective 
study continuous EEG monitoring had additional prog-
nostic information for poor outcome  [85] , but there are no 
data that outcome is improved by continuous EEG moni-
toring. Of all 8 instances of non-convulsive status epilep-
ticus detected by continuous EEG monitoring in 101 co-
matose SAH patients, only 1 patient temporarily improved 
after antiepileptic treatment, and all 8 patients eventually 
died  [84] . Since prolonged EEG recording is expensive, la-
bour intensive, subject to misinterpretation  [86] , and lacks 
proof of effectiveness, there are no grounds to use it as part 
of the routine monitoring strategy in patients with SAH.
 Predictive factors for epileptic seizures have not been 
identified. Intracranial surgery increases the risk  [87] , but 
a randomized trial of antiepileptic drugs after supratento-
rial craniotomy for benign lesions (not only aneurysms) in 
276 patients failed to show benefit in terms of seizure rate 
or case fatality, although the CIs were wide  [88] . Also, an 
observational study performed on 3,552 patients partici-
pating in 4 prospective, randomized, double-blind, place-
bo-controlled trials suggested that outcome was worse in 
the 65% of patients receiving prophylactic antiepileptic 
drugs than in the other 35% of patients who did not receive 
prophylactic antiepileptic medication  [89] . Given the lack 
of evidence in favour of prophylactic treatment with anti-
epileptic drugs and the possible disadvantage of serious 
adverse drug reactions, the current advice should be not to 
start antiepileptic drugs as prophylactic treatment.
 Recommendation for Seizure Management 
 • Antiepileptic treatment should be administered in patients 
with clinically apparent seizures (GCP) 
 • There is no evidence that supports the prophylactic use of an-
tiepileptic drugs (class IV, level C) 
 Steroids 
 A Cochrane review last updated in 2005 found 1 pla-
cebo-controlled trial on hydrocortisone in patients with 
SAH  [90] . There was no difference in clinical outcome 
between patients with secondary ischaemia treated with 
hydrocortisone and those treated with placebo, but the 
risk of hyperglycaemia almost doubled  [90] . A random-
ized trial published after the Cochrane review showed 
that in patients treated with hydrocortisone, serum so-
dium level and plasma osmolarity were controlled better 
than in controls, but clinical outcome was not better  [91] . 
Based on these studies, routine hydrocortisone for pa-
tients with SAH is not warranted.
 Statement on the Use of Steroids
 • There is no proof that steroids are effective in patients with 
SAH (class IV, level C) 
 Specific Prevention of Rebleeding 
 General Considerations – Timing 
 Up to 15% of patients rebleed during the first few hours 
after the initial haemorrhage  [92] , that is, during trans-
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portation or before the treatment team is able to occlude 
the aneurysm. Patients surviving the first day after the 
initial SAH have a cumulative risk of 35–40% to suffer 
rebleeding of the aneurysm with a mortality rate of about 
40%. After 4 weeks the risk of rebleeding decreases to 
about 3%/year  [93] .
 The primary goal of the treatment of aneurysmal SAH 
is the occlusion of the ruptured aneurysm, i.e. to close the 
bleeding source preventing a rebleeding. For this, two 
major treatment options are available: neurosurgical clip-
ping and endovascular coiling. A meta-analysis of 11 out 
of 268 studies with a total of 1,814 patients revealed in a 
comparative evaluation of early versus late surgical clip-
ping of ruptured aneurysms that early treatment (within 
72 h after SAH) of patients with a good clinical/neuro-
logical condition on admission (WFNS 1–3) leads to a 
significantly better outcome. A similar trend, without 
statistical significance, could be detected in patients with 
worse WFNS grades of 4–5  [94] . Even earlier treatment 
(within 12 h) of SAH patients with WFNS grades IV and 
V did not increase the number of dependent survivors 
 [95] . Although there are no good evidence-based data, a 
general long-lasting consensus exists that ruptured aneu-
rysms of patients with good and moderate clinical SAH 
grades (WFNS 1–4; Hunt and Hess grade I–IV) should be 
treated in the early phase after the initial bleeding (<72 h 
after SAH). In patients presenting with multiple intracra-
nial aneurysms, i.e. with one ruptured aneurysm causing 
SAH and several unruptured incidental aneurysms, the 
ruptured aneurysm is primarily treated. Subsequent 
treatment of the unruptured incidental aneurysms de-
pends on clinical course after SAH, outcome, age, size, 
location and configuration of the aneurysm.
 Recommendation for Timing of Intervention 
 • Aneurysm should be treated as early as logistically and tech-
nically possible to reduce the risk of rebleeding; if possible it 
should be aimed to intervene at least within 72 h after onset 
of first symptoms 
 • This decision should not depend on grading 
 (class III, level C)
 Neurosurgical Clipping and Endovascular Coiling of 
Ruptured Aneurysm 
 In the early beginnings of cerebral aneurysm treat-
ment, surgery was the only approach for RIAs. Starting 
with proximal ligation of vessels (trapping) like the ca-
rotid artery and followed by wrapping of the aneurysm 
with muscle tissue to strengthen the aneurysm wall to 
prevent rebleeding, surgical aneurysm treatment is now-
adays based on clip occlusion (clipping). Although trap-
ping and wrapping as sole therapeutic approaches are an-
tiquated, both methods are exceptionally used in combi-
nation with other surgical techniques such as aneurysm 
clipping and/or bypass surgery. Since the development of 
aneurysm clips, risk of rebleeding significantly decreased. 
With the establishment of microsurgery, surgical ap-
proaches became smaller and less traumatizing. Further-
more, intra-operative indocyanine green angiography 
and Doppler sonography lead to extra intra-operative 
quality control  [96] . After the invention of detectable 
platinum coils by G. Guglielmi in 1990, an alternative to 
surgical clipping developed.
 Clip versus Coil 
 To compare both therapeutic approaches, clipping and 
coiling, factors including morbidity, mortality, complete 
and durable occlusion of the aneurysm, rebleeding (intra- 
and postprocedural aneurysm rupture) and others have 
to be evaluated: The International Subarachnoid Aneu-
rysm Trial (ISAT) was a randomized controlled trial that 
compared clipping and coiling (without balloon or stent 
techniques)  [87, 97] . The ISAT study followed the ‘uncer-
tainty principle’. The main inclusion criterion of ISAT 
was that an RIA seemed equally accessible and treatable 
by either surgical clipping or endovascular coiling (‘clin-
ical equipoise’). This inclusion criterion was met by 22.4% 
of patients (2,143 of 9,559 patients) with RIAs treated dur-
ing the study period at the study centres. The remaining 
77.6% of patients suffered from aneurysms which were 
preferably treated by either coiling or clipping. Those pa-
tients were not randomized and were excluded from the 
study. Besides a highly selected patient cohort, ISAT was 
also criticized for its high (90%) proportion of patients 
with good clinical grades after SAH (Hunt and Hess 
grades 1–2) and underrepresentation of middle cerebral 
artery aneurysms, which are often anatomically more 
difficult to be coiled than aneurysms in other locations. 
However, for this subpopulation of ruptured aneurysms, 
which were equally coilable or clippable, ISAT showed 
that endovascular coiling had an advantage over surgical 
clipping, with better clinical outcome: absolute risk re-
duction of death and severe disability after 1 year was 
6.9% in favour of coiling versus clipping, based on the 
observation that 23.7% of endovascular-treated patients 
(compared to 30.6% of patients after clipping) stayed se-
verely disabled or died after 1 year  [97] . The 9-year follow-
up of ISAT also revealed a reduction in the relative 5-year 
mortality risk in favour of coiling. No difference could be 
observed in the amount of independent SAH survivors 






as well as follow-up ISAT analysis showed that patients 
treated with coiling had a higher rebleeding risk, which 
was comparable to the risk of suffering SAH from a new 
aneurysm  [97, 98] . The postoperative risk of rebleeding 
appears to be associated with the degree of insufficient 
aneurysm occlusion. Another follow-up study of the pa-
tients treated in the ISAT was performed to compare the 
frequency and consequences of aneurysm recurrence. 
Retreatment was performed in 17.4% of patients after pri-
mary endovascular coiling and in 3.8% of patients after 
neurosurgical clipping. Late retreatment was 6.9 times 
more likely after coiling. Younger age, larger lumen size, 
and incomplete occlusion were risk factors for late re-
treatment after coiling  [99] . A post hoc modelling study 
with mortality as outcome parameter only after coiling 
and clipping for patients from the ISAT emphasized that 
no advantage of coil embolization over clip ligation can 
be assumed for patients younger than 40 years. For these 
patients clipping might even be the better treatment op-
tion in terms of life expectancy  [100] .
 Because of the highly selected aneurysm subpopula-
tion in ISAT, ISAT results cannot be generalized. Recent 
studies, which consider increasing endovascular treat-
ment during the last years, could not detect any differ-
ence in mortality and morbidity between coiling and 
clipping  [101, 102] .
 The Cerebral Aneurysm Rerupture after Treatment 
(CARAT) trial was a non-randomized trial that included 
1,010 patients with SAH from 1996 to 1998 and followed 
them up in 2005. Coiling was applied in 299 and clipping 
in 711 patients. After a mean observation period of 4 
years it turned out that the degree of aneurysm occlusion 
after treatment was strongly associated with risk of re-
rupture. The overall risk of rerupture tended to be great-
er after coil embolization compared with surgical clip-
ping, but the difference did not persist after adjustment 
 [103] . Intraprocedural aneurysm rupture and bleeding is 
common in patients undergoing treatment of RIAs. In 
the CARAT study patient collective the intraprocedural 
rupture rate was 5% with endovascular and 19% with sur-
gical treatment. The risk of intraprocedural rupture-as-
sociated death/disability was doubled in the endovascu-
lar group (63% coiling vs. 31% clipping)  [104] .
 Further results from 2 randomized trials which re-
cently stopped recruitment are awaited: the HELPS study 
(HydroCoil Endovascular Aneurysm Occlusion and 
Packing study)  [105] , comparing hydrogel-coated coils 
with standard platinum coils and the Cerecyte Coil study 
 [106] , which compares polymer-coated coils with stan-
dard platinum coils.
 Summarizing the current studies, ruptured aneu-
rysms are complex lesions. The primary goal of treatment 
should be a complete occlusion of the aneurysm sack to 
reduce postprocedural rerupture and bleeding. In the 
case of aneurysms which can be treated equally with clip-
ping or coiling, without stent or balloon (clinical equi-
poise), endovascular therapy is preferred. However, indi-
cations and treatments should be discussed in an inter-
disciplinary dialogue. In the case of an accompanying 
space occupying intracerebral hematoma, surgical treat-
ment and clipping is favoured.
 As a rough guidance, aneurysms with a wide neck, 
branching vessels out of the aneurysm sack, middle ce-
rebral artery aneurysms or patients with intracerebral 
hematoma should preferably be treated by clipping, 
while aneurysms of the basilar artery or elderly pa-
tients (patients >70 years, small aneurysm neck, poste-
rior circulation) should be coiled (level B)  [104] . Any 
decision concerning treatment should be interdisci-
plinary and based on the experience and treatment re-
sults of the neurosurgeon and endovascular radiolo-
gist, and should be adapted to the individual aspects 
including parameters such as age, general state of 
health, location, configuration and size of the aneu-
rysm, as well as the request of the patient. RIAs should 
be treated in centres that offer high-quality treatment 
with both modalities.
 Recommendation for Interventional Prevention of Rebleeding 
 • The best mode of intervention should be discussed in an in-
terdisciplinary dialogue between Neurosurgery and Neuro-
radiology 
 • Based on this discussion patients should be informed and in-
cluded in the process of decision making whenever possible 
 • In cases where the aneurysm appears to be equally effectively 
treated either by coiling or clipping, coiling is the preferred 
treatment (class I, level A) 
 • In general, the decision on whether to clip or coil depends on 
several factors related to 3 major components: 
(1)  Patient: age, comorbidity, presence of ICH, SAH grade, 
aneurysm size, location and configuration, as well as on 
status of collaterals (class III, level B) 
(2)  Procedure: competence, technical skills and availability 
(class III, level B) 
(3)  Logistics: the grade of interdisciplinarity (class III, level B) 
 In patients with aneurysmal SAH:
 • Factors in favour of operative intervention (clipping) are: 
younger age, presence of space occupying ICH (class II, level 
B), and aneurysm-specific factors such as: 
 –  location: middle cerebral artery and pericallosal aneu-
rysm (class III, level B) 
 – wide aneurysm neck (class III, level B) 
 –  arterial branches exiting directly out of the aneurysmal 
sack (class III, level B) 
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 –  other unfavourable vascular and aneurysmal configura-
tion for coiling (class IV, level C)  [97, 103, 107] 
 • Factors in favour of endovascular intervention (coiling) are: 
age above 70 years, (class II, level B), space occupying ICH not 
present (class II, level B), and 
 aneurysm-specific factors such as: 
 – posterior location  
 – small aneurysm neck  
 – unilobar shape (class III, level B)  [97, 103] . 
 • Elderly patients should not per se be excluded from treatment; 
decisions whether or not to treat depend on the clinical and 
physical condition of the patients 
 Antifibrinolytic Treatment 
 Antifibrinolytic Drugs.  In a Cochrane review includ-
ing 9 randomized trials of antifibrinolytic drugs in SAH, 
antifibrinolytic treatment reduced the risk of rebleeding 
but did not influence death from all causes or a poor 
outcome  [108] . A Swedish trial published after the last 
update tested a strategy where tranexamic acid was giv-
en as soon as SAH had been diagnosed in the local hos-
pital (before the patients were transported) and contin-
ued until aneurysm occlusion, which was typically per-
formed within 72 h  [109] . Again the overall outcome did 
not appreciably improve in patients treated with 
tranexamic acid, despite an impressive reduction in re-
bleeding. If this trial is pooled with the 9 other trials 
included in the Cochrane review, there is still no effect 
on overall outcome  [110] . Further trials with ultra-early 
and short-term tranexamic acid should be performed 
before this therapy can be implemented in clinical prac-
tice.
 Recombinant Factor VIIa.  Theoretically, recombinant 
factor VIIa might prevent rebleeding. An open-label, 
dose escalation safety study was suspended when the 
10th patient developed middle cerebral artery branch 
occlusion contralateral to the aneurysm  [111] . In an un-
controlled series of 18 patients who received an intra-
operative dose during surgical occlusion of a ruptured 
aneurysm, no episodes of rebleeding occurred, but 1 pa-
tient developed deep venous thrombosis and 7 an upper 
extremity venous thrombosis in association with pe-
ripherally inserted central catheter lines  [111] . At this 
moment, there is no evidence to support the use of re-
combinant factor VIIa outside study protocols in pa-
tients with SAH.
 Statement 
 • There is currently no medical treatment that improves out-
come by reducing rebleeding (class I, level A) 
 • Results from some small trials that used haemostatic agents 
suggest further investigations with modified protocols (class 
II, level C) 
 Hydrocephalus 
 Hydrocephalus, defined as a bicaudate index on the 
CT scan exceeding the 95th percentile for age, occurs in 
approximately 20% of patients during the acute phase 
and in about 10% during the chronic phase after SAH 
 [112] . Acute hydrocephalus may be caused by obstruction 
of the CSF flow in the tentorial hiatus by extensive haem-
orrhage in the perimesencephalic cisterns, or in the ven-
tricles by frank intraventricular haemorrhage  [113, 114] . 
In about a third of these patients hydrocephalus is asymp-
tomatic, and half of the patients with initial hydrocepha-
lus and impairment of consciousness improve spontane-
ously within 24 h  [112] .
 Patients with acute hydrocephalus may be in poor 
neurological condition immediately after SAH and have 
dilated ventricles on the CT scan. Such acute hydroceph-
alus is related to the amount of intraventricular haemor-
rhage rather than SAH  [112, 115] . 
 Some neurosurgeons prefer not to use a ventricular 
drain in these patients immediately as half of them will 
improve spontaneously and there is a risk of rebleeding 
and infection. An alternative approach, which can be rec-
ommended, is to start immediate external ventricular 
drainage (keeping intracranial pressure between 10 and 
20 mm Hg) in all these patients if there is no other obvi-
ous explanation  (such as massive ICH) for a reduced lev-
el of consciousness (level IV evidence)  [112, 116] . On the 
other hand, ventriculostomy increases risk for rebleeding 
and meningitis/ventriculitis  [117] .
 It has been suggested to apply lumbar drainage as a 
consecutive treatment of external ventricular drainage 
before shunting in patients with spontaneous ICH when 
the third and fourth ventricles are free of blood, i.e. com-
municating hydrocephalus. This approach may be con-
sidered as an alternative approach to reduce the frequen-
cy of permanent shunts, but is important to pay attention 
to downward herniation in case of supratentorial swelling 
and the development of hygroma. So far no prospective 
clinical trial has proven efficacy of this approach either 
for spontaneous ICH or patients with SAH  [118, 119] .
 Recommendations for Hydrocephalus Management 
 • In patients with CT-proven hydrocephalus and the third or 
fourth ventricle filled with blood, an external ventricular 
drain should be applied; this drain can be used to reduce and 
monitor pressure and to remove blood; for this last reason the 
level of evidence is low (GCP) 
 • In patients who are not sedated and who deteriorate from 
acute hydrocephalus, lumbar puncture might be considered 
if the third and fourth ventricle are not filled with blood and 






 • In patients who are sedated and have CT-proven hydrocepha-
lus, lumbar drainage should be considered if the third and 
fourth ventricles are not filled with blood (class IV, level C) 
 • Patients with symptomatic chronic hydrocephalus require 
ventriculo-peritoneal or ventriculo-atrial shunting (GCP) 
 Prevention of Delayed Ischemic Deficit 
 Pharmacological Prevention/Treatment 
 A Cochrane review, including 16 trials with 3,361 pa-
tients with SAH, found a relative risk of 0.81 (95% CI, 0.72–
0.92) for death or dependence in the patients treated with 
calcium antagonists; the corresponding number of pa-
tients needed to treat was 19 (95% CI, 1–51)  [120] . For oral 
nimodipine alone the RR was 0.67 (95% CI, 0.55–0.81); for 
other calcium antagonists or intravenous administration 
of nimodipine the results were not statistically significant. 
Calcium antagonists reduced the occurrence of secondary 
ischaemia and showed a favourable trend for case fatality. 
Although the risk reduction for ‘poor outcome’ is statisti-
cally robust, it depends mainly on a single large trial  [121] , 
and therefore the benefits of nimodipine cannot be regard-
ed as being beyond all reasonable doubt. The practical im-
plication is that the regimen in the dominant nimodipine 
trial (60 mg orally every 4 h for 3 weeks) is currently re-
garded as the standard treatment in patients with aneurys-
mal SAH. If the patient is unable to swallow, the nimodip-
ine tablets should be coarse-grained crushed and washed 
down a nasogastric tube with normal saline within min-
utes. Intravenous administration is advocated by the man-
ufacturer and is more expensive, but there is no evidence 
to support this  [120] . Moreover, intravenous administra-
tion of nicardipine does not improve outcome  [120] .
 Calcium antagonists have also been applied into the 
subarachnoid space after surgical occlusion of the aneu-
rysm, but this strategy is of unproven benefit  [122, 123] .
 Recommendation on Pharmacological Prevention of Delayed 
Ischemic Deficit with Nimodipine
 • Nimodipine should be administered orally (60 mg/4 h) to pre-
vent delayed ischaemic events (class I, level A) 
 • In case oral administration is not possible nimodipine should 
be applied intravenously (GCP) 
 Other Pharmacological Measures to Prevent Delayed 
Ischaemic Events 
 Smaller single-centre studies showed a positive effect 
of statins on the development of cerebral vasospasm, DCI 
and mortality. However, the recently published placebo-
controlled randomized trial results and meta-analysis did 
not show any effect of statins on the development or clin-
ical outcome of cerebral vasospasm after SAH  [124, 125] .
 Magnesium reduced the frequency of DCI in a dose-
dependent fashion  [126] . The Mash-2 (Magnesium for 
Aneurysmal Subarachnoid Haemorrhage) trial is a 
phase-3 controlled trial that randomized 606 SAH pa-
tients to intravenous treatment with magnesium sulphate 
(64 mmol/day) and 597 patients with SAH to placebo. 
Treatment with magnesium did not improve outcome. A 
meta-analysis of 7 randomized controlled trials revealed 
that magnesium treatment is not superior to placebo in 
the reduction of poor outcome  [127] .
 Recommendation on Other Pharmacological Prevention of 
 Delayed Ischaemic Events 
 • Magnesium sulphate is not recommended for the prevention 
of DCI (class I, level A) 
 • Statins are under study 
 Hemodynamic Management of Delayed Ischemic 
Deficit 
 Thirty-five years after the first published observation 
 [128] , randomized trials on induced hypertension are still 
lacking, but on the basis of case reports and uncontrolled 
series many physicians have used induced hypertension 
and hypervolaemia and seen their patients improve. The 
risks of deliberately increasing arterial pressure and plas-
ma volume include increased cerebral oedema, haemor-
rhagic transformation in areas of infarction  [129] , revers-
ible leucencephalopathy  [130] , myocardial infarction and 
congestive heart failure.
 Statement on Hemodynamic Management of Delayed Isch-
aemic Deficit
 • There is no evidence from controlled studies for induced hy-
pertension or hypervolaemia to improve outcome in patients 
with delayed ischaemic deficit (class IV, level C) 
 SAH without Aneurysm 
 Epidemiology and Definition 
 In about 15% of non-traumatic SAH no bleeding 
source is found by DSA (see Diagnosis). In these cases we 
differentiate between perimesencephalic and non-
perimesencephalic location of the SAH, because these de-
termine further therapeutic approach.
 Perimesencephalic SAH 
 The diagnosis ‘perimesencephalic SAH’ (PMSAH) is de-
fined by exclusion of an aneurysmatic bleeding and typical 
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location of blood within the perimesencephalic and pre-
pontine cisterns (i.e. no blood in sylvic and interhemispher-
ic fissure)  [131, 132] . Though blood sedimentation in the 
ventricles may occur, occlusion of ventricles or parenchy-
mal bleeding is not in line with the definition of PMSAH.
 Imaging alone is not sufficient to make the diagnosis 
of PMSAH, because bleeding sources may be the cause of 
this bleeding, as vertebrobasilar aneurysm or arteriove-
nous malformation. The risk of making the diagnosis, on 
the one hand, is determined by the overall annual inci-
dence rates for SAH and PMSAH: 8.7 (95% CI, 7.9–9.5) 
and 0.5 (95% CI, 0.3–0.7) per 100,000 persons aged  ≥ 18, 
respectively  [133] . On the other hand stands the risk (2–
3%) of intra-arterial DSA  [134, 135] . At the same time 
CTA and MRA were found to have high sensitivity of ex-
cluding aneurysmal bleedings in PMSAH  [136, 137] . 
Whether this justifies the decision not to perform DSA in 
PMSAH still needs to be proven by larger prospective 
studies. However, repeat angiography in the case of nega-
tive baseline DSA after PMSAH is not recommended, 
since the procedural risk outweighs the chance of finding 
an aneurysm  [131, 132, 138, 139] .
 Clinically, PMSAH seems to present milder with less 
severe outcome than diffuse SAH without aneurysm 
 [140] . The occurrence of vasospasm and the association 
with DCI may be low  [141–143] . The prophylactic applica-
tion of nimodipine (and other calcium antagonists) can-
not be recommended until more studies demonstrate the 
relevance of DCI in PMSAH.
 Apart from DCI and rebleeding, other complications 
like hydrocephalus, hyponatremia and electrographic 
changes may be as frequent in PMSAH as they are in an-
eurysmal SAH  [144] . These complications should be 
treated as recommended above.
 Rebleeding seems not to play a role in long-term prog-
nosis and survival of PMSAH is not decreased  [132, 139, 
145] . All these observations indicate that the cause of PM-
SAH is not arterial bleeding, but may be due to variants 
of infratentorial venous drainage  [146] .
 Non-Perimesencephalic SAH 
 Almost all studies that deal with non-perimesence-
phalic SAH with no bleeding source in the baseline DSA 
are retrospective  [141, 147–151] . However, the frequency 
of positive findings in a follow-up angiography in these 
studies ranged between 5 and 35%. Therefore, repeat an-
giography is recommended in non-perimesencephalic 
SAH without bleeding source.
 Non-Traumatic SAH of Other Causes 
 Non-traumatic SAH can be caused by various other, 
non-aneurysmatic causes ( table 3 ). Diagnoses and treat-
ment of these SAH cases need to be performed according 
specifically to the underlying cause.
 Recommendation on Diagnostic Procedure in SAH without 
 Aneurysm 
 • In patients with PMSAH a DSA should only be performed if 
the CTA was not considered to be sufficient or if there is doubt 
on the perimesencephalic pattern of the SAH (class II, level B) 
 • In the case of non-perimesencephalic location of the bleeding 
with typical pattern of SAH, CTA or DSA should be repeated 
not earlier than 3 weeks after the initial bleeding if there are 
no other therapeutic indications to perform the studies ear-
lier (class III, level B) 
 Unruptured Intracranial Aneurysms 
 Epidemiology 
 Since SAH is still a serious disease with high rates of 
case fatality and morbidity, unruptured aneurysms, when 
incidentally discovered or found in connection with di-
agnosis of ruptured aneurysm (multiple aneurysm cases), 
have been operated on for decades in western countries. 
Unruptured aneurysms are usually classified as follows: 
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asymptomatic incidental aneurysms, symptomatic aneu-
rysms, and unruptured (additional) aneurysms in SAH 
patients (multiple aneurysm cases). By occlusion of an 
unruptured aneurysm, the high case fatality and morbid-
ity associated with a possible severe SAH can be elimi-
nated by preventive surgical or endovascular interven-
tion. However, natural history, risks of endovascular 
treatment and surgery of UIAs, and risk factors for rup-
ture remain unclear as studies with sufficient numbers of 
patients and follow-up years are lacking.
 Thus far, there are only few prospective follow-up 
studies and several small retrospective ones evaluating 
the natural history of UIAs. Furthermore, patient popu-
lations of different studies have been more or less selected 
for important predictive factors, surgery and patient age.
 Table 4 shows cohorts of the 2 largest published pro-
spective studies of rupture risk of UIAs (class II/III, level 
B recommendation)  [41–43] . The prospective part of The 
International Study of Unruptured Intracranial Aneu-
rysms (ISUIA; patient enrolment in 61 centres between 
1991 and 1998) shows somewhat different results com-
pared with those of the retrospective part of ISUIA (in 53 
centres between 1970 and 1991)  [41, 152] . In the prospec-
tive study, overall incidence of aneurysm rupture was 
higher (0.8 vs. 0.3% per year), risk for rupture of vertebro-
basilar aneurysms was lower (relative risk 2.3 vs. 5.1–13.8 
compared with other aneurysms), mean follow-up time 
per patient was shorter (3.9 vs. 8.3 years), there was a low-
er limit of aneurysm diameter for very low risk for rup-
ture in patients without a prior SAH (<7 vs. <10 mm), and 
there was a non-significant direct association between 
patient age and aneurysm rupture risk compared with 
the results obtained in the retrospective study.
 Although ISUIA included a large number of patients, 
differences between results of prospective and retrospec-
tive ISUIA studies suggest selection bias. Therefore, re-
sults of ISUIA may be difficult to generalize to patient 
populations with unruptured aneurysms, and the results 
should be noted with some caution. In addition, among 
adults aged >30 years, annual incidence rates of SAH are 
at least 30–40 per 100,000, and estimated aneurysm prev-
alence rates for adults are 2–5%  [9, 11, 12, 153] . Thus, ex-
pected rupture incidence of unruptured aneurysms in 
the general adult population should be at least 1% per 
year. Rupture risks reported by the ISUIA may be some-
what underestimated, which is also suggested by the fact 
that the majority of the ruptured aneurysms are <10 mm 
in diameter.
 Patients of the ISUIA were collected from the time pe-
riod when UIAs were operated on to a great extent, par-
ticularly in patients of working age, as was seen in the 
high proportion of patients (58%) who were operated on 
with either open or endovascular surgery  [41] . Patients 
whose unruptured aneurysms were operated on with 
open surgery were younger and significantly (p < 0.01) 
more likely current cigarette smokers than those with no 
surgery  [41] . There were also several other significant dif-
ferences between groups of open surgery, endovascular 
treatment and no treatment concerning the most impor-
tant predicting factors for rupture or outcome after pos-
sible treatment. These include aneurysm size and loca-
tion as well as different medical or behavioural factors.
 The results of a prospective natural history study of 
unruptured aneurysms from the Helsinki University 
Central Hospital (patient enrolment in 1 centre between 
1956 and 1978) have been reported several times since 
1960 as the number of patients and follow-up years in-
creased with elapsed time  [23, 42, 153, 154] . This cohort 
had a long-term follow-up (mean 18.2, median 19.7 years 
per patient), had no surgical selection and had a complete 
follow-up of cases with unruptured aneurysms, but the 
number of patients (n = 142) was modest compared with 
that of ISUIA and almost all were patients of working age, 
had high prevalence of smoking, and had multiple aneu-
rysms with the ruptured aneurysm clipped at start of fol-
low-up  [42, 153] . So, these results cannot necessarily be 
generalized to those patients of advanced age who have 
incidentally found aneurysms. Patients with incidental 
aneurysms are now increasingly found on either MRA or 
3D CTA. On the other hand, the annual rupture rate of 
1.3% (95% CI, 0.9–1.7%) was similar to that of smaller 
previously published retrospective patient series (1–3%) 
and remained almost constant for 25 years after diagno-
sis. Significant risk factors for aneurysm rupture were 
cigarette smoking (tested also as a time-dependent co-
variate), aneurysm diameter (linear association) and age, 
inversely  [42].  High systolic blood pressure values and 












ISUIA-03 1,692 51 6,544 0.8 1, 2
Juvela-00-03 142 34 2,577 1.3 1, 3, 4
 Risk factors: 1 = aneurysm diameter, 2 = aneurysm location, 
3 = cigarette smoking and 4 = patient age.
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long-term hypertension during follow-up predicted fatal 
aneurysm rupture  [23] . Although patients with multiple 
aneurysms have an increased risk for aneurysm forma-
tion, they do not have an increased risk for rupture of 
unruptured aneurysm compared with those with a single 
unruptured aneurysm  [41, 42, 152, 153] .
 When deciding means of treatment of unruptured an-
eurysm, one must take into account not only the maxi-
mum diameter of the aneurysm  [41, 42] but also patient 
age  [42] , location of aneurysm (posterior communicating 
and vertebrobasilar aneurysms may have higher rupture 
risk)  [41] , history of hypertension  [23] and previous SAH 
(not an independent risk factor for rupture)  [41] , as well as 
cigarette smoking  [42] . In the prospective part of ISUIA, 
risks of treatment were similar in the open surgical and 
endovascular treatment groups  [41] . On the other hand, 
patients treated more commonly with endovascular coil-
ing procedures than with open surgery were those who 
also had higher risks for poor outcome after operative 
treatment (older age, larger aneurysms, more frequently 
basilar tip aneurysms). However, aneurysmal obliteration 
with endovascular treatment was complete in only 51% of 
cases, and durability of treatment remained unknown due 
to a short follow-up time. Although endovascular coiling 
has been shown to be effective in the prevention of re-
bleeding after aneurysmal SAH  [97] , its use for the treat-
ment of unruptured aneurysms is not so evident, particu-
larly in young adults, since benefit of treatment cannot be 
seen until a follow-up of several decades. Incomplete coil-
ing of large aneurysms (failures of organization of intra-
aneurysm thrombus, complete fibrous aneurysm obliter-
ation and endothelization of aneurysm orifice) can lead to 
a recanalization and unexpected growth and rupture of 
aneurysm during follow-up  [155] , and these aneurysms 
are difficult to treat later with open surgery. However, 
coiling of unruptured aneurysms may be useful in an old-
er patient with a basilar tip aneurysm which is not large 
(<12 mm) and has a narrow neck, as well as in those who 
have had previous cerebral ischaemia  [41, 155] .
 Risks of open surgery of unruptured aneurysms of the 
ISUIA (mortality 1.5–2.3%, disability 10–12%)  [41] were 
similar to those obtained in a meta-analysis (overall mor-
tality 2.6%, permanent disability 10.9%)  [156] . Poor out-
come with open surgery was independently predicted by 
aneurysm size, posterior circulation aneurysm, advanced 
age and previous ischaemic cerebrovascular disease  [41] . 
Poor outcome with endovascular treatment was indepen-
dently predicted by aneurysm size and posterior circula-
tion aneurysm  [41] . In the ISUIA, 11% of patients with 
aneurysm occlusion by open surgery had cerebral infarc-
tion, while 5% of those with endovascular aneurysm oc-
clusion had such a lesion. However, durability and overall 
treatment risks of endovascular treatment are unknown 
in a long-term follow-up. Thus, open surgery of unrup-
tured aneurysms should continue, at least by those neu-
rosurgeons having postoperative infarct risk of  ≤ 5% in 
aneurysm surgery.
 In the meta-analysis, technically difficult aneurysms 
were overrepresented [giant aneurysms (>25 mm) 27%, 
posterior circulation aneurysms 30%]  [156] . Thus, these 
favourable results were probably affected by publication 
bias. Authors calculated the following unfavourable re-
sults for specific aneurysm groups: anterior non-giant 
aneurysms, mortality 0.8% and morbidity 1.9%; posterior 
non-giant aneurysms, 3.0 and 12.9%; anterior giant an-
eurysms 7.4 and 26.9%, and posterior giant aneurysms 
9.6 and 37.9%, respectively  [156] .
 As estimated from the above-mentioned studies, op-
erative treatment should be considered for all unruptured 
aneurysms in patients aged <50 to 60 years (open surgery) 
as well as perhaps for aneurysms of  ≥ 7 mm in diameter 
in older patients (open surgery or endovascular treat-
ment) if there are no contraindications and patients have 
no serious pre-existing diseases  [41, 42] . Advanced age 
and history of ischaemic cerebrovascular disease favour 
the use of endovascular treatment  [41] .
 Patients with symptomatic aneurysms should be can-
didates for the treatment of aneurysm occlusion irrespec-
tive of age since symptoms may be due to a minor leak or 
growing aneurysm that predicts a major rupture. Final 
techniques of treatment of unruptured aneurysms de-
pend on the experience of neurosurgeons and neuroradi-
ologists of each centre. Finally, cessation of cigarette 
smoking and active treatment of hypertension are impor-
tant for patients with unruptured aneurysms irrespective 
of the methods of treatment of these lesions  [23, 42] .
 Treatment 
 Clipping or Coiling 
 Statement on Intervention in UIA 
 • Although endovascular procedures might be associated with 
less immediate risk, the long-term risk and durability of treat-
ment are not known and data from prolonged follow-up of 
treated patients are needed 
 • Data indicate there exists a state of clinical equipoise in the 
management of a significant proportion of UIAs; this impres-
sion is reinforced by the broad variation in management for 






against intervention is a decision of the individual case taking 
into account patient-dependent factors (age, cigarette smok-
ing and perhaps rupture from other aneurysm), aneurysmal 
factors (size, location), and the assumed risk of the interven-
tion; therefore, the decision should be based on a multidisci-
plinary discussion of the individual case (class III, level C) 
Recommendation on Intervention in UIA
 • The larger the aneurysm the higher the chance of rupture 
(class II, level B) 
 • Considering risk (procedural risk, range 5–50%, vs. sponta-
neous rupture risk, 0–10%, per year) and benefit (life expec-
tancy with or without minor deficit), the decision for or 
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